Sharon D. Kemp

6.3k citations

29 papers · 5.4k indexed · 4 hit papers · h-index 25

Infectious Diseases top 0.1%
Virology top 0.05%
Epidemiology top 2%
Molecular Biology top 10%
Hepatology top 2%

Co-authors: Brendan Larder P. Richard Harrigan Paul Kellam Margaret Tisdale G. Darby N. R. Parry Stuart Bloor M H St Clair
Topics: HIV Research and Treatment (23 papers)HIV/AIDS drug development and treatment (23 papers)HIV/AIDS Research and Interventions (16 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United Kingdom Germany Canada

In The Last Decade

Sharon D. Kemp

29 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)

1989 980 citations Brendan Larder, Sharon D. Kemp Science profile →
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase

1991 587 citations M H St Clair, J L Martin et al. Science profile →
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

1993 523 citations Margaret Tisdale, Sharon D. Kemp et al. Proceedings of the National Academy of Sciences profile →
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy

1995 518 citations Brendan Larder, Sharon D. Kemp et al. Science profile →

Peers

Countries citing papers authored by Sharon D. Kemp

Since Specialization

Citations

This map shows the geographic impact of Sharon D. Kemp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon D. Kemp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon D. Kemp more than expected).

Fields of papers citing papers by Sharon D. Kemp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon D. Kemp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon D. Kemp. The network helps show where Sharon D. Kemp may publish in the future.

Co-authorship network of co-authors of Sharon D. Kemp

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon D. Kemp. A scholar is included among the top collaborators of Sharon D. Kemp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon D. Kemp. Sharon D. Kemp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples 2000 ·AIDS ·Kurt Hertogs,Stuart Bloor,Sharon D. Kemp,Christel Van den Eynde,Timothy M. Alcorn,Rudi Pauwels,Margriet Van Houtte,Schlomo Staszewski,Veronica Miller,Brendan Larder	157
2	Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy 2000 ·The Journal of Infectious Diseases ·P. Richard Harrigan,Christopher Stone,(unknown),Isabel Nájera,Stuart Bloor,Sharon D. Kemp,Margaret Tisdale,Brendan Larder,(unknown)	127
3	Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting 1999 ·AIDS ·P. Richard Harrigan,Kurt Hertogs,Werner Verbiest,Rudi Pauwels,Brendan Larder,Sharon D. Kemp,Stuart Bloor,Benita Yip,Robert S. Hogg,Christopher W. Alexander,Julio Montaner	101
4	Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‐Lamivudine Combination Therapy: Association with Therapy Failure 1998 ·The Journal of Infectious Diseases ·Veronica Miller,Andrew Phillips,(unknown),Schlomo Staszewski,Rudi Pauwels,Kurt Hertogs,Marie‐Pierre de Béthune,Sharon D. Kemp,Stuart Bloor,P. Richard Harrigan,Brendan Larder	74
5	The M184 V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors 1998 ·AIDS ·Veronica Miller,Martin Stürmer,Schlomo Staszewski,Bettina Gröschel,Kurt Hertogs,Marie‐Pierre de Béthune,Rudi Pauwels,P. Richard Harrigan,Stuart Bloor,Sharon D. Kemp,Brendan Larder	63
6	A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs 1998 ·Antimicrobial Agents and Chemotherapy ·Kurt Hertogs,Marie‐Pierre de Béthune,Veronica Miller,Tania Ivens,(unknown),(unknown),Christel Van den Eynde,(unknown),Hilde Azijn,Margriet Van Houtte,(unknown),Schlomo Staszewski,Marcus A. Conant,Stuart Bloor,Sharon D. Kemp,Brendan Larder,Rudi Pauwels	338
7	Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group 1996 ·Journal of Virology ·Brendan Larder,Arinder Kohli,Stuart Bloor,Sharon D. Kemp,P. Richard Harrigan,Robert T. Schooley,Joep M. A. Lange,Kevin N. Pennington,M H St Clair	43
8	ANTIVIRAL POTENCY OF AZT + 3TC COMBINATION THERAPY IN VIVO SUPPORTS IN VITRO VIROLOGICAL OBSERVATIONS 1994 ·AIDS ·Sharon D. Kemp,P. Richard Harrigan,(unknown),Arinder Kohli,Brendan Larder	1
9	A PLACEBO CONTROLLED TRIAL OF AZT ALONE OR IN COMBINATION WITH DDI OR DDC 1994 ·AIDS ·P. Richard Harrigan,Sharon D. Kemp,(unknown),Stuart Bloor,Arinder Kohli,(unknown),(unknown)	3
10	Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro 1993 ·Nature ·(unknown),Paul Kellam,Sharon D. Kemp	125
11	Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing 1993 ·Nature ·Brendan Larder,Arinder Kohli,Paul Kellam,Sharon D. Kemp,Mel N. Kronick,(unknown)	164
12	Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3‘-azido-3‘-deoxythymidine. 1992 ·Journal of Biological Chemistry ·Simon F. Lacey,John E. Reardon,Eric S. Furfine,Thomas A. Kunkel,Katarzyna Bębenek,Kelvin Eckert,Sharon D. Kemp,Brendan Larder	107
13	Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes 1991 ·AIDS ·(unknown),Paul Kellam,Sharon D. Kemp	233
14	Mutational analysis of two conserved sequence motifs in HIV‐1 reverse transcriptase 1991 ·FEBS Letters ·Denise M. Lowe,(unknown),Sharon D. Kemp,Brendan Larder	70
15	Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptasebreakdown → 1991 ·Science ·M H St Clair,J L Martin,Gareth Tudor‐Williams,(unknown),Cindy Vavro,David M. King,Paul Kellam,Sharon D. Kemp,Brendan Larder	587
16	Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture 1991 ·Journal of Virology ·Brendan Larder,(unknown),Sharon D. Kemp	142
17	Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors 1989 ·Journal of Antimicrobial Chemotherapy ·Margaret Tisdale,Brendan Larder,Denise M. Lowe,D.K. Stammers,D. J. M. Purifoy,Peter Ertl,(unknown),Sharon D. Kemp,G. Darby,K. L. Powell	8
18	Characterization of a DNA Polymerase Mutant of Herpes Simplex Virus from a Severely Immunocompromised Patient Receiving Acyclovir 1989 ·Journal of General Virology ·Peter Collins,Brendan Larder,(unknown),Sharon D. Kemp,I. W. Smith,G. Darby	84
19	The Role of Herpes Simplex Virus Type 1 Thymidine Kinase in Pathogenesis 1989 ·Journal of General Virology ·Stacey Efstathiou,Sharon D. Kemp,G. Darby,A. C. Minson	195
20	Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. 1989 ·Proceedings of the National Academy of Sciences ·Brendan Larder,Sharon D. Kemp,D. J. M. Purifoy	145

About Sharon D. Kemp

Sharon D. Kemp is a scholar working on Virology, Infectious Diseases and Genetics, having authored 29 papers that have together received 5.4k indexed citations. Recurring topics across this work include HIV Research and Treatment (23 papers), HIV/AIDS drug development and treatment (23 papers) and HIV/AIDS Research and Interventions (16 papers). The work is most often cited by research in Virology (4.4k citations), Infectious Diseases (4.4k citations) and Hepatology (350 citations). Sharon D. Kemp has collaborated with scholars based in United Kingdom, Germany and Canada. Frequent co-authors include Brendan Larder, P. Richard Harrigan, Paul Kellam, Margaret Tisdale, G. Darby, N. R. Parry, Stuart Bloor, M H St Clair, Rudi Pauwels and Kurt Hertogs. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact